Google DeepMind has announced that AlphaFold 3, the latest version of its protein structure prediction system, has solved a protein-ligand binding problem that has stumped chemists for over 200 years. The breakthrough could dramatically accelerate drug discovery and cut development costs by billions of dollars.
The system can now predict, with near-perfect accuracy, how drug molecules will bind to target proteins β the critical step in determining whether a new compound will work as a medicine. Previously, this required years of laboratory experiments and often failed late in expensive clinical trials.
"This is not incremental progress. This changes the economics of drug discovery entirely," said Dr. Demis Hassabis, CEO of DeepMind.
Pharmaceutical companies including Pfizer, Roche, and Novartis have already begun integrating AlphaFold 3 into their drug discovery pipelines. Early results suggest the time to identify viable drug candidates could shrink from 5-7 years to less than 18 months.
